Complete financial analysis of LIGAND PHARMACEUTICAL INC (LGNZZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of LIGAND PHARMACEUTICAL INC, a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Halliburton Company (HAL.SW) Income Statement Analysis – Financial Results
- Man Yue Technology Holdings Limited (0894.HK) Income Statement Analysis – Financial Results
- T & I Global Limited (TIGLOB.BO) Income Statement Analysis – Financial Results
- Nexion Technologies Limited (8420.HK) Income Statement Analysis – Financial Results
- Nerdy, Inc. (NRDY-WT) Income Statement Analysis – Financial Results
LIGAND PHARMACEUTICAL INC (LGNZZ)
Industry: Medical - Pharmaceuticals
Sector: Healthcare
About LIGAND PHARMACEUTICAL INC
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 131.31M | 196.25M | 241.54M | 186.42M | 120.28M | 251.45M | 141.10M | 108.97M | 71.91M | 4.81M | 9.02M | 4.39M | 3.77M | 6.84M | 9.12M | 2.28M | 7.66M | 3.65M |
| Cost of Revenue | 43.29M | 77.10M | 96.27M | 56.14M | 53.58M | 22.13M | 17.49M | 16.21M | 5.81M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 88.03M | 119.15M | 145.27M | 130.28M | 66.70M | 229.32M | 123.62M | 92.76M | 66.11M | 4.81M | 9.02M | 4.39M | 3.77M | 6.84M | 9.12M | 2.28M | 7.66M | 3.65M |
| Gross Profit Ratio | 67.03% | 60.71% | 60.14% | 69.89% | 55.45% | 91.20% | 87.61% | 85.12% | 91.93% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 25.42M | 36.25M | 32.23M | 57.12M | 30.54M | 27.86M | 26.89M | 21.22M | 13.38M | 36.36M | 40.92M | 30.31M | 21.46M | 16.68M | 15.05M | 12.61M | 9.46M | 7.66M |
| General & Administrative | 52.79M | 70.06M | 57.48M | 64.44M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | -10.69M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 52.79M | 70.06M | 46.79M | 64.44M | 41.88M | 37.73M | 28.65M | 26.62M | 24.38M | 10.75M | 12.44M | 10.89M | 5.28M | 3.80M | 2.96M | 2.53M | 2.13M | 1.45M |
| Other Expenses | 0.00 | 87.06M | 9.57M | 53.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 78.21M | 106.31M | 79.02M | 121.55M | 72.42M | 65.60M | 55.54M | 47.84M | 37.76M | 47.11M | 53.36M | 41.20M | 28.44M | 22.11M | 18.51M | 15.16M | 11.60M | 9.11M |
| Cost & Expenses | 121.49M | 183.41M | 175.29M | 177.69M | 126.00M | 87.73M | 73.03M | 64.06M | 43.57M | 47.11M | 53.36M | 41.20M | 28.44M | 22.11M | 18.51M | 15.16M | 11.60M | 9.11M |
| Interest Income | 7.71M | 2.05M | 886.00K | 8.08M | 28.43M | 14.00M | 0.00 | 0.00 | 0.00 | 916.00K | 3.10M | 3.93M | 1.30M | 531.00K | 177.00K | 378.00K | 0.00 | 0.00 |
| Interest Expense | 656.00K | 1.80M | 19.62M | 27.42M | 35.75M | 48.28M | 11.40M | 12.18M | 11.80M | 933.00K | 556.00K | 391.00K | 210.00K | 228.00K | 226.00K | 295.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 37.41M | 43.39M | 41.34M | 27.97M | 43.73M | 16.69M | 12.52M | 11.29M | 2.63M | 2.07M | 192.00K | 678.00K | 2.79M | 2.53M | 1.17M | 460.00K | -7.86M | -10.91M |
| EBITDA | 101.73M | 81.20M | 107.59M | 44.85M | 38.01M | 180.42M | 80.60M | 31.43M | 30.98M | -40.22M | -44.15M | -36.13M | -21.88M | -12.75M | -8.21M | -12.43M | -3.93M | -5.46M |
| EBITDA Ratio | 77.47% | 28.65% | 44.54% | 19.69% | 31.60% | 71.75% | 57.12% | 51.58% | 43.07% | -836.26% | -489.48% | -823.78% | -580.19% | -186.49% | -90.03% | -545.65% | -51.29% | -149.38% |
| Operating Income | 9.82M | 12.84M | 66.25M | 8.73M | -5.72M | 163.73M | 68.08M | 44.92M | 28.35M | -42.30M | -44.34M | 36.81M | 24.67M | 15.28M | 9.38M | 12.89M | 3.93M | 5.46M |
| Operating Income Ratio | 7.48% | 6.54% | 27.43% | 4.68% | -4.76% | 65.11% | 48.25% | 41.22% | 39.42% | -879.36% | -491.61% | 839.24% | 654.12% | 223.42% | 102.84% | 565.63% | 51.29% | 149.38% |
| Total Other Income/Expenses | 53.84M | 23.17M | 5.95M | -19.27M | 802.36M | 9.60M | -10.85M | -36.96M | 6.98M | -42.30M | -9.12M | -36.81M | -9.87M | -15.28M | -9.38M | -12.89M | -3.93M | -5.46M |
| Income Before Tax | 63.66M | 36.01M | 72.21M | -10.54M | 796.64M | 173.33M | 57.23M | 7.96M | 35.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.39M | 12.89M | 0.00 | 0.00 |
| Income Before Tax Ratio | 48.48% | 18.35% | 29.89% | -5.65% | 662.31% | 68.93% | 40.56% | 7.30% | 49.13% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 102.87% | 565.85% | 0.00% | 0.00% |
| Income Tax Expense | 9.84M | 41.23M | -4.15M | -7.55M | 167.34M | 30.01M | 44.68M | 10.33M | -192.12M | 17.00K | -2.54M | -3.54M | -1.09M | -303.00K | 46.00K | -88.00K | 7.61M | 10.65M |
| Net Income | 52.15M | -33.36M | 57.14M | -2.99M | 629.30M | 143.32M | 12.56M | -2.37M | 229.82M | -42.31M | -41.80M | -33.27M | -23.58M | -14.97M | -9.43M | -12.80M | -3.68M | -5.19M |
| Net Income Ratio | 39.72% | -17.00% | 23.66% | -1.60% | 523.19% | 57.00% | 8.90% | -2.17% | 319.58% | -879.71% | -463.45% | -758.50% | -625.30% | -218.98% | -103.34% | -561.76% | -48.04% | -142.13% |
| EPS | 3.02 | -1.98 | 3.44 | -0.18 | 33.13 | 6.77 | 0.60 | -0.11 | 11.61 | -1.25 | -1.37 | -1.15 | -1.20 | -1.49 | -6.55 | -10.12 | -4.44 | -13.05 |
| EPS Diluted | 2.94 | -1.98 | 3.31 | -0.18 | 31.85 | 5.96 | 0.53 | -0.11 | 10.83 | -1.25 | -1.37 | -1.15 | -1.20 | -1.49 | -5.96 | -10.12 | -4.44 | -13.05 |
| Weighted Avg Shares Out | 17.30M | 16.87M | 16.63M | 16.18M | 19.00M | 21.16M | 21.03M | 20.83M | 19.79M | 33.78M | 30.59M | 29.02M | 19.71M | 10.03M | 1.44M | 1.26M | 830.00K | 398.00K |
| Weighted Avg Shares Out (Dil) | 17.76M | 16.87M | 17.25M | 16.18M | 19.76M | 24.07M | 23.48M | 20.83M | 21.23M | 33.78M | 30.59M | 29.02M | 19.71M | 10.03M | 1.58M | 1.26M | 830.00K | 398.00K |
Source: https://incomestatements.info
Category: Stock Reports